AR054259A1 - Vacuna contra virus de papiloma humano (hpv) - Google Patents

Vacuna contra virus de papiloma humano (hpv)

Info

Publication number
AR054259A1
AR054259A1 AR20060101619A ARP060101619A AR054259A1 AR 054259 A1 AR054259 A1 AR 054259A1 AR 20060101619 A AR20060101619 A AR 20060101619A AR P060101619 A ARP060101619 A AR P060101619A AR 054259 A1 AR054259 A1 AR 054259A1
Authority
AR
Argentina
Prior art keywords
hpv
protein
vaccine
immunogenic fragment
against human
Prior art date
Application number
AR20060101619A
Other languages
English (en)
Spanish (es)
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36992675&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR054259(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0509010A external-priority patent/GB0509010D0/en
Priority claimed from PCT/EP2005/006461 external-priority patent/WO2005123125A1/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of AR054259A1 publication Critical patent/AR054259A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AR20060101619A 2005-04-26 2006-04-24 Vacuna contra virus de papiloma humano (hpv) AR054259A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67482905P 2005-04-26 2005-04-26
GB0509010A GB0509010D0 (en) 2005-05-03 2005-05-03 Vaccine
PCT/EP2005/006461 WO2005123125A1 (en) 2004-06-16 2005-06-14 Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52

Publications (1)

Publication Number Publication Date
AR054259A1 true AR054259A1 (es) 2007-06-13

Family

ID=36992675

Family Applications (1)

Application Number Title Priority Date Filing Date
AR20060101619A AR054259A1 (es) 2005-04-26 2006-04-24 Vacuna contra virus de papiloma humano (hpv)

Country Status (12)

Country Link
US (1) US20090181052A1 (enExample)
EP (1) EP1877086A2 (enExample)
JP (1) JP2008539184A (enExample)
KR (1) KR20080005585A (enExample)
AR (1) AR054259A1 (enExample)
AU (1) AU2006239422A1 (enExample)
CA (1) CA2606092A1 (enExample)
EA (1) EA013326B1 (enExample)
MX (1) MX2007013472A (enExample)
NO (1) NO20075194L (enExample)
SG (1) SG159525A1 (enExample)
WO (1) WO2006114312A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
RS53607B1 (sr) * 2008-07-31 2015-04-30 Glaxosmithkline Biologicals S.A. Vakcina protiv hpv
AU2009348078B2 (en) * 2009-06-19 2013-03-14 Eyegene Inc. Vaccine for cervical cancer
WO2012177970A1 (en) 2011-06-24 2012-12-27 Merck Sharp & Dohme Corp. Hpv vaccine formulations comprising aluminum adjuvant and methods of producing same
US11638754B2 (en) 2020-02-14 2023-05-02 Merck Sharp & Dohme Llc HPV vaccine
US20230048144A1 (en) 2021-08-06 2023-02-16 Merck Sharp & Dohme Llc Hpv vaccine
MX2024002144A (es) 2021-08-19 2024-04-23 Merck Sharp & Dohme Llc Nueva nanoparticula lipidica termostable y metodos de uso de la misma.
TW202513091A (zh) 2023-06-09 2025-04-01 美商默沙東有限責任公司 用於人類乳突病毒疫苗之奈米乳液佐劑組合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB9921147D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
US6908613B2 (en) * 2000-06-21 2005-06-21 Medimmune, Inc. Chimeric human papillomavirus (HPV) L1 molecules and uses therefor
GB0105606D0 (en) * 2001-03-07 2001-04-25 Cantab Pharmaceuticals Res Ltd Immunogens and vaccines and their preparation and use
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
JP5475939B2 (ja) * 2002-12-20 2014-04-16 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｈｐｖ−１６およびｈｐｖ−１８ｌ１ｖｌｐワクチン
MY140664A (en) * 2003-09-29 2010-01-15 Merck Sharp & Dohme Optimized expression of hpv 45 l1 in yeast

Also Published As

Publication number Publication date
WO2006114312A3 (en) 2007-04-05
EP1877086A2 (en) 2008-01-16
AU2006239422A1 (en) 2006-11-02
JP2008539184A (ja) 2008-11-13
MX2007013472A (es) 2008-04-02
SG159525A1 (en) 2010-03-30
EA013326B1 (ru) 2010-04-30
EA200702079A1 (ru) 2008-04-28
KR20080005585A (ko) 2008-01-14
CA2606092A1 (en) 2006-11-02
US20090181052A1 (en) 2009-07-16
WO2006114312A2 (en) 2006-11-02
NO20075194L (no) 2008-01-18

Similar Documents

Publication Publication Date Title
AR040204A1 (es) Composicion de vacuna meningococica multivalente
CY1121211T1 (el) Εμβολιο ιου ερπητα ζωστηρα
ECSP045300A (es) Antígenos virales
NO20082472L (no) Vaksinesammensetninger omfattende en saponin adjuvant
PT1187629E (pt) Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
MY169275A (en) Method of immunization against the four serotypes of dengue
BRPI0510430A (pt) composições e métodos para vacinação mucosal
BR112012000287B8 (pt) composição farmacêutica para um inibidor de protease viral de hepatite c
AR041880A1 (es) Composicion inmunogena
ATE309821T1 (de) Influenzavirus-impfstoffzusammensetzung
WO2007052155A3 (en) Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
WO2009095226A3 (en) NUCLEIC ACIDS COMPRISING FORMULA (NuGlXmGnNv)a AND DERIVATIVES THEREOF AS AN IMMUNOSTIMULATING AGENTS /ADJUVANTS
UY26724A1 (es) Métodos y composiciones para tratar el virus de la hepatitis c
WO2009060281A3 (en) Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties
CO2019000214A2 (es) Vacuna contra virus de bronquitis infecciosa
AR055603A1 (es) Vacuna contra la infeccion por virus del dengue
DE60336225D1 (de) Neue pharmazeutische zusammenstezungen, flibanserin polymorph a enthaltend
AR042530A1 (es) Vacuna que comprende particulas viroides del virus papiloma humano 16 y 18
AR071741A1 (es) Vacunas contra la malaria
CO6341567A2 (es) Vacuna contra el virus de papiloma humano
BR112022015313A2 (pt) Vacina de hpv
AR054259A1 (es) Vacuna contra virus de papiloma humano (hpv)
MX2022006742A (es) Uso y composicion farmaceutica de derivados de fenilisoxazolil metilen-naftaleno-eter.
BRPI0414073A (pt) método para induzir uma resposta imune contra infecção por rotavìrus a partir de um sorotipo de rotavìrus, e, uso de uma cepa de rotavìrus atenuado de um sorotipo
BRPI0516314A (pt) uso de hiv inteiro e método de tratamento de um indivìduo cronicamente infectado com hiv

Legal Events

Date Code Title Description
FA Abandonment or withdrawal